NEW YORK (GenomeWeb News) – Sigma-Aldrich today said it is partnering with the Scripps Research Institute to develop and commercialize new reagents.

The deal, the company said, will "fund research and provide immediate day-of-publication access to [Scripps] researchers' discoveries for the synthesis and analysis of potential drugs," and, further, could "eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."